Effect of proton pump inhibitors in infants with esophageal atresia on the gut microbiome: a pilot cohort

Gut Pathog. 2022 Dec 16;14(1):47. doi: 10.1186/s13099-022-00518-9.

Abstract

Background: The effects of proton-pump inhibitors (PPIs) on the infant microbiome remain unclear. Swedish pilot cohort study to assess the longitudinal effect of long-term PPI on the infant gut microbiome, including ten newborn infants operated for esophageal atresia exposed to PPIs (mean 57 weeks), compared to healthy one-year-old controls. All children were born vaginally and were otherwise healthy. Within- and between sample diversity of the fecal microbiome was assessed using untargeted whole genome Shotgun metagenomics which sequences all the DNA in the sample and can capture genes rather than a taxonomic fingerprint.

Results: A longer duration of PPI-use was associated with considerable changes in evenness and high variation on diversity within samples compared to a shorter duration of use. The limited difference between baseline samples and controls suggests that this shift was most likely due to the drug exposure and not the underlying alterations on the microbiome. We found no associations with the number of antibiotic treatment episodes among the PPI-users.

Conclusion: Prolonged PPI-use may alter the early infant gut microbiome composition, especially those with the most prolonged duration of use.

Keywords: Esophageal atresia; Gastric acid; Infants; Microbiome; PPI; Proton pump inhibitor.